The Most Popular Growth Hormone Peptide Has Zero Human Trials

CJC-1295 sells in two versions that share one name, and neither has a human trial record to stand on. This article sorts the naming chaos and walks the evidence tier from zero human data down to zero mouse data, ending on why the cheap price mostly reflects an underdosed vial. It is community-sourced protocol analysis assembled for research purposes, it is not medical advice, and nothing here is a treatment claim for any condition.

I · The most popular secretagogue with the emptiest evidence file

By the community’s own topic counts, CJC-1295 and its mod-GRF variant drew more than fifty comment threads in a single sourcing cluster, ⁵ and the dominant voice in that cluster is a prolific community educator, a knowledgeable amateur the subreddits know as Tracy. His answer to what the evidence file contains is settled: “There are zero clinical trials for CJC-1295 no DAC” and there “aren’t even any published mouse studies” behind it. ¹ The absence is the story, because a peptide with this much shelf presence should have a dossier, and the dossier is missing, which is why his running joke is that “it doesn’t even have any mouse studies, let alone human ones, so we can assume anything about it that we want”. ⁴

The safety side of the file is just as empty, and the educator’s shorthand is blunt: “There’s basically no safety profile for mod-GRF.” ³ That sentence covers what a normal drug package would contain, and none of it exists for this molecule, so there is no pharmacokinetic curve or immunogenicity readout and no reference point for an overdose. The sharpest version comes from his reply to someone who called the compound safe, and it is worth quoting in full:

I love how this subreddit’s idea of “safe” is a drug that doesn’t even have any mouse trials, let alone a human one.

Community educator, Reddit peptide discourse, 2025-2026

The betting offer on the same theme is the cleanest summary of the evidence tier: “There’s no major human data on CJC-1295 no DAC. There’s no minor human data either. Hell, I’ll send you $20 in BTC if you can find me any mouse data for CJC-1295 no DAC.” ² No one collected the twenty dollars, because the searches come back empty, and each protocol number and schedule in circulation is community invention layered on an empty file. ²

II · The slightly modified sermorelin under the CJC-1295 name

The molecule under the name is a growth hormone releasing hormone analog, which places it in the GHRH class of secretagogues alongside tesamorelin and sermorelin, and the class works by telling the pituitary to release the growth hormone it already makes, unlike ghrelin-class drugs like ipamorelin, which release growth hormone and stimulate appetite. ⁷ The educator’s description of what these analogs do is disarmingly simple: “They both just cause pulsatile GH release, that’s it”, and the punchline is that “It’s the GH that is doing the work”, since the secretagogue is the messenger and the growth hormone is the payload. ⁷ That pulse pattern matters, because natural growth hormone release is rhythmic, a series of peaks rather than a steady stream, and a GHRH analog that mimics the pulse keeps the system in its normal physiological shape.

The specific molecule sold as CJC-1295 no DAC is mod-GRF(1-29), which the educator describes as a “slightly modified sermorelin” built on four amino acid substitutions, ⁶ and the shorthand is precise because sermorelin is the pharma version of the first 29 amino acids of the natural releasing hormone. The four substitutions are the whole difference between the studied molecule and the unstudied one, since sermorelin has adult trial data while the modified version carries the same skeleton and none of the paperwork, which is why the educator’s framing is that CJC no DAC “has never been trialed in humans but it’s extremely similar to sermorelin”. ⁹ Part of the reason the modified version exists is that the real sermorelin stopped being produced more than a decade ago, so the gray market needed a familiar-name substitute, and the altered fragment filled the shelf space. ⁸

The naming logic gets stranger from here, because the name encodes a subtraction, and the educator’s analogy is a food order: “So when you say CJC-1295 no DAC, you’re basically saying CJC-1295 with DAC but remove the DAC… kinda like “I want a cheeseburger, hold the cheese.”” ⁹ The joke works because the cheeseburger without cheese is a different sandwich, and the no-DAC peptide is a different molecule than the DAC version, which means the most popular growth hormone peptide in the gray market is defined by what was removed rather than by what it is. ⁹

III · The other CJC-1295, the one with the DAC

The other half of the name covers a different drug, because the DAC version carries a modification that keeps the peptide circulating for days rather than minutes. ¹¹ The educator’s description of the difference is that the DAC form produces “chronic basal GH elevation” with a half-life measured in days, whereas the no-DAC form is pulsatile and short-lived, and his blunt summary of the pairing is that “With regards to CJC-1295 with DAC vs no DAC, they really should be treated as two unrelated drugs. They have substantially different effects.” ¹² The community’s own usage reflects that separation, since the DAC version is essentially absent from the protocol discourse, because the sustained elevation and weekly injection schedule it implies carry consequences few people volunteer for, which the educator summarizes as the “substantial downsides” of weekly dosing. ¹³

The research record for the DAC version is its own kind of empty, because although the molecule was studied enough to be named and manufactured, the educator’s point is that “nobody actually knows what the half-life of CJC-1295 s/ DAC is because it’s never been researched in humans”, ¹³ and the antibody question sits right next to that gap, since a peptide with days-long circulation is the kind of biologic that provokes an immune response. The community’s antibody baseline comes from the incretin trials, where the reading is that roughly half of tirzepatide patients develop antibodies without losing the drug’s effect, ¹⁵ which tells the researcher an antibody titer is a finding rather than automatically a failure, but also that antibody responses are common enough to expect, and for the DAC version the response was never studied in humans at all. ¹⁵ Both versions are biologics, the educator’s counter to the folk belief that one provokes antibodies while the other is clean, since any injected foreign protein is an antigen-presentation event, and the absence of human data leaves the question open. ¹⁵

The contrast is worth holding in one frame, because the no-DAC version mimics the natural pulse while the DAC version opens a steady background elevation, two endocrine states entirely, and the educator’s myth table dispatches the interchangeability claim with a single line: “Might as well be completely different drugs”. ¹⁴ The practical consequence is that a user who thinks they are buying the famous name and receiving one pharmacology may be receiving the other, which is why the label confusion matters. ¹⁴

IV · One name that covers two unrelated drugs

The naming chaos is structural rather than accidental, because vendor sheets list CJC-1295, CJC-1295 no DAC, mod-GRF, and blends like CJC-1295 with ipamorelin as one product family, when the two are molecules with opposite release patterns and a shared label. ¹⁴ The educator’s correction for anyone buying the real thing is that “If you really want to get into the weeds, what vendors typically call “CJC-1295 with DAC” is actually just CJC-1295″, ¹⁰ which means the original molecule is the DAC version, and the wildly popular no-DAC version is the modified knockoff that inherited the famous name. The confusion flows both directions, since a shopper who wants the pulse-mimicking version can receive the basal version or vice versa, and neither the label nor the puck size tells them which one they hold, which is where the community’s testing culture enters. ¹⁰

The phantom literature layer sits on top of the label chaos, because the CJC-1295 “studies” circulating in forums are part of the fake-citation epidemic the community’s fact-checkers have documented, with the retatrutide-adjacent influencer Trevor Bachmeyer named as the public example of citations that do not exist, and the unfindable CJC-1295 studies as the case that keeps resurfacing. ¹⁶ The pattern is worth naming precisely, because a molecule with zero real trials is a vacuum that fake citations rush into, since no one can check a study against an empty record, and the community’s diagnosis is that hallucinated references spread because the underlying claim feels plausible. ¹⁶

The practical discipline is the community’s testing norm, because when the label cannot tell you what is in the vial, the mass and purity test can, and the standard practice is a kit-of-ten arrangement in which nine vials stay with the buyer and one goes to a lab, cost shared across the group. ¹⁷ The educator’s framing of vendor certificates is that they are advertisements rather than guarantees, which is why the community treats independent testing as the load-bearing check, and why the label question resolves to a single question: what did the test say. ¹⁷

V · Why the cheap price mostly means an underdosed vial

The pricing story starts in the supply chain, where the educator’s anatomy of the gray market is that a Chinese API vendor sells to a finishing lab which lyophilizes and fills vials, which a reseller then marks up, and his summary of the retail layer is that resellers take the product at “$0.50/mg, putting a sticker on it, marking it up 1000%, and selling it to you for $5/mg”. ¹⁷ The markup alone does not explain CJC’s reputation for being cheap, because the real reason sits one layer deeper, and the educator’s labwork makes the mechanism visible: his own IGF-1 follow-ups showed a modest bump on a low-dose mod-GRF stack, roughly double at a higher mod-GRF dose, and a much larger jump on tesamorelin at its approved dose. ¹⁸ His conclusion from that ladder is the article’s thesis in miniature: CJC’s cheapness is “mostly just that it’s underdosed”, ¹⁸ because the convention range produces a small response for the simple reason that the dose is a small dose, and the price per vial reflects the amount of molecule rather than the amount of effect.

The underdosing pattern is the class problem rather than the molecule’s alone, because the educator’s standing comparison is that sermorelin’s adult trials needed a daily dose far above anything the protocol sheets prescribe before IGF-1 moved, whereas tesamorelin at its approved dose lifts IGF-1 by over 100%, ¹⁹ the gap between a studied dose and a guessed one. His hedge on the convention range is telling, since he allows that the two “both seem to work reasonably well” before noting the range has no trial data, ¹⁸ which is the difference between a dose that was found and a dose that was guessed, and the guess is what the gray market prices. The pecking order he teaches follows the same logic, since tesamorelin sits above sermorelin and CJC no DAC in his ranking while exogenous growth hormone sits above all of them, because at doses that actually work the secretagogue path usually costs more per unit of IGF-1 than the hormone itself. ¹⁹

The honest math is price per effect rather than price per vial, because a cheap vial that moves IGF-1 a little is more expensive than a pricier one that moves it a lot, which is how the bargain peptide becomes the expensive option. ¹⁸ The community-synthesized equivalence that CJC matches tesamorelin milligram for milligram is marked as a synthesis rather than a measured fact, ¹⁹ and even if it holds it strengthens the point, because matching tesamorelin’s output at the approved dose would require the unstudied molecule to run at a dose no one has validated in any species.

VI · Reading the empty file honestly

The honest reading of the evidence tier is that the file stays empty, and the only real-world signals available are the community’s own reports, anecdotes rather than data. ²⁰ The best-documented of those is the flush, since the educator’s identification of the symptom is matter-of-fact: “The hot flash is CJC-1295 if you’re using that”, ²⁰ and his triage note is that a flush is normal while hives are the worrying sign, the difference between a transient vascular response and a possible immune reaction. ²⁰ The class reputation for allergic reactions sits alongside that, since the community hears “about people having allergic reactions to a few of the popular ones (cjc, tesa, mots) pretty frequently”, ²¹ and the educator’s practical response is blunt: “Just switch to GH. Why play around with a class of peptides where every option seems to cause allergic reactions?” ²¹

The immunogenicity question deserves the same honesty, because a molecule with zero human data has zero human immunogenicity data, and every injection is an antigen-presentation event whether the product is sterile or not, which is why the community filters product. ¹⁵ For a researcher who still chooses to work with this molecule, the discipline is the same one the educator applies to the whole class: baseline IGF-1, a follow-up draw after a month, and periodic checks, with the dose adjusted to the response, since labwork is the only instrument that tells the truth about a drug with no published numbers. ²²

The open question at the end of the empty file is who would ever fill it, because a modified fragment of a discontinued pharma peptide has no patent runway and no sponsor, so the phase 1 that would answer those questions is unlikely to be funded, and the evidence tier will probably stay where it is. ²² That is the real takeaway, since the choice for a researcher is between a studied option like tesamorelin, which has registration trials and an approved dose behind it, and an unstudied option whose dossier is community lore, and the educator’s ranking makes the direction clear. ¹⁹

This article is community-sourced protocol analysis assembled for research purposes; it is not medical advice, and it is not a treatment claim for any condition. CJC-1295 no DAC has no human trial data and no published mouse studies, so anything the community believes about it is a hypothesis, and anyone handling these peptides should do so under appropriate oversight with tested product and honest labwork.